SQ22536-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
SQ22536-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
SQ22536-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
SQ22536-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESQ22536Cat.No.:HY-100396CASNo.:17318-31-9分?式:C?H??N?O分?量:205.22作?靶點(diǎn):AdenylateCyclase作?通路:GPCR/GProtein儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(487.28mM;Needultrasonic)H2O:55mg/mL(268.01mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM4.8728mL24.3641mL48.7282mL5mM0.9746mL4.8728mL9.7456mL10mM0.4873mL2.4364mL4.8728mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;?旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(12.18mM);Clearsolution2.請(qǐng)依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(12.18mM);Clearsolution3.請(qǐng)依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(12.18mM);Clearsolution4.請(qǐng)依序添加每種溶劑:PBSSolubility:25mg/mL(121.82mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性SQ22536?種有效的腺苷酸環(huán)化酶(AC)抑制劑。IC50&Targetadenylatecyclase(AC)[1]體外研究SQ22536(SQ22,536)effectivelyinhibitstheeffectofforskolinwithrespectiveIC50valuesof5μM.PreincubationwithgradedconcentrationsofSQ22536revealsthatbothSQ22536effectivelyinhibitsPACAP-inducedreportergeneactivationwithapproximateIC50valueof5μM.SQ22536morepotentlyinhibitsforskolin-inducedElkactivation(IC50=10μM)than8-Br-cAMP-inducedElkactivation(IC50=170μM).Mostnotably,therearesubstantialdifferencesinthereportedpotenciesofSQ22536toinhibittheactivitiesofrecombinantAC5andAC6,withrespectiveIC50valuesof2μMand360μM.Atagreaterconcentration(500μM),SQ22536significantlyinhibitsneuriteelongationduetoeitherforskolinor8-Br-cAMP[1].PROTOCOLCellAssay[1]HEK293CRE-luc2PGloResponseluciferasereportercellsaretransducedwithretroviralvectorsexpressingratPAC1hopreceptors.Individualcelllinesareobtainedbylimitingdilutioncloning,andaclonalPAC1-expressinglineispropagatedandusedforCREluciferaseassays.Inbrief,HEK293CRE-luc2Pcellsareplatedin96-wellplates(10,000cellsin80μLmediaperwell)inassaymedia(DMEMsupplementedwith1%fetalbovineserum).Onedayafterplating,cellsaretreatedwithACinhibitors(10μLinassaymedia/well)for30minutes,followedbyagonists(10μLinassaymedia/well),andareincubatedfor4hours.Luciferaseactivityisdeterminedaftertheadditionof100μL/wellBright-GloLuciferaseAssayReagent.Luminescence(RLU)ismeasuredinaVictor3microtiterplatereaderafter2minutesofagitationatroomtemperature.CyclicAMPismeasuredinNS-1cells.Inbrief,NS-1cellsareseededandgrownovernightin96-wellplates.Thenextday,cellsarepretreatedfor20minutesinmediacontainingthephosphodiesteraseinhibitor3-isobutyl-1-methylxanthine(0.5mM)withorwithoutSQ22536.Afterpretreatmentwithinhibitors,cellsarestimulatedwithagonists,addedas10×solutions,foranadditional20minutes.IntracellularcAMPisthenassayedusingthecAMPBiotrakenzymeimmunoassaykitformeasurementofnonacetylatedcAMP[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?ProgNeurobiol.2021Mar22;102041.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?CellDeathDis.2020May26;11(5):394.?IntJMolSci.2022,23(20),12595.?IntJMolSci.2022Sep14;23(18):10709.?iScience.2021,102812.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].EmeryAC,etal.AnewsiteandmechanismofactionforthewidelyusedadenylatecyclaseinhibitorSQ22,536.MolPharmacol.2013Jan;83(1):95-105.McePdfHe

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論